Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 3/20 | 0.44 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340838 | 0.81 | PSEN1 (0.54) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1896511 | 0.81 | DYRK1A (0.65) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL30308690 | 0.81 | DYRK1A (0.65) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31380443 | 0.81 | ROCK2 (0.45) | ROCK2ROCK1AAK1 | |
| SCHEMBL4903193 | 0.81 | ROCK2 (0.45) | ROCK2ROCK1AAK1 | |
| SCHEMBL1492706 | 0.80 | DYRK1A (0.61) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2615984 | 0.80 | DYRK1A (0.61) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6855459 | 0.79 | DYRK1A (0.66) | DYRK1APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL27447623 | 0.79 | NISCH (0.42) | DYRK1A | |
| SCHEMBL19759543 | 0.79 | ROCK2 (0.44) | MAP4K4ROCK2ROCK1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795159-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2015-12-03 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795159-B2 | Compounds for the treatment of SARS | ACE2, ACE, SARS1 | DYRK1A 4771/4885PSEN1 1754/4885PSEN2 1348/4885 |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | USP1, UHRF1, UBQLN1 | DYRK1A 2717/4885PSEN1 3120/4885PSEN2 4017/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | DYRK1A 4362/4885PSEN1 1081/4885PSEN2 1497/4885 |
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | DYRK1A 698/4885PSEN1 2558/4885PSEN2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.